来源:经济观察网经济观察网 根据公开信息,九源基因(02566.HK)在2026年有以下值得关注的事件:行业政策与环境司美格鲁肽专利到期及市场竞争变化:司美格鲁肽核心专利将于2026年3月后到期,预计国产司美格鲁肽将进入市场竞争加剧的阶段,九源基因是申报该产品的企业之一。产品研发进展创新药JY54注射液临床试验进展:公司于2026年2月9日公告JY54注射液(长效胰淀素类似物)临床试验申请获受理,...
Source Link来源:经济观察网经济观察网 根据公开信息,九源基因(02566.HK)在2026年有以下值得关注的事件:行业政策与环境司美格鲁肽专利到期及市场竞争变化:司美格鲁肽核心专利将于2026年3月后到期,预计国产司美格鲁肽将进入市场竞争加剧的阶段,九源基因是申报该产品的企业之一。产品研发进展创新药JY54注射液临床试验进展:公司于2026年2月9日公告JY54注射液(长效胰淀素类似物)临床试验申请获受理,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.